文献速递药物相互作用药物不良反应与药物警戒

利福平对贝尼地平对映体处置及降压效应的影响

Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine.
PubMed 文献 · Br J Clin Pharmacol · 2019-01-30

在健康受试者中开展的交叉设计研究显示,单次服用外消旋贝尼地平后,(S)-(S)-(+)-α异构体暴露约为(R)-(R)-(-)-α异构体的三倍。重复给予利福平显著降低两种异构体的暴露(Cmax和AUC∞的GMR均在0.10-0.14),口服清除率增加约10倍,但健康受试者血压效应无显著差异。

要点

  • 贝尼地平对映体处置具有立体选择性,(S)异构体暴露约为(R)异构体的3倍
  • 利福平使贝尼地平两异构体Cmax和AUC∞的GMR降至0.10-0.14
  • 健康受试者中利福平对贝尼地平降压效应影响不大,但需在高血压患者中评估

核心结论

  • 单次给予外消旋贝尼地平后观察到(S)-(S)-(+)-α和(R)-(R)-(-)-α贝尼地平的对映选择性处置。
  • 重复给予利福平显著降低两种异构体的暴露,但在健康受试者中对其降压效应影响似乎有限。
  • 利福平与贝尼地平合用对降压疗效的影响应在高血压患者中进一步评估。

研究设计与样本

  • 健康受试者交叉设计研究,贝尼地平8 mg单次给药,联用或不联用重复利福平给药。
  • 给药后24小时内测定贝尼地平(S)-(S)-(+)-α和(R)-(R)-(-)-α异构体血浆浓度及血压。
  • 采用咪达唑仑口服清除率评估每名受试者的CYP3A代谢能力。

主要发现

  • 单次给予贝尼地平后,(S)-(S)-(+)-α-贝尼地平暴露约为(R)-(R)-(-)-α-贝尼地平的3倍。
  • 利福平使(S)-(S)-(+)-α-贝尼地平Cmax和AUC∞的GMR(95%CI)分别为0.14(0.10-0.18)和0.12(0.08-0.18)。
  • 利福平使(R)-(R)-(-)-α-贝尼地平Cmax和AUC∞的GMR(95%CI)分别为0.10(0.06-0.17)和0.10(0.06-0.17)。
  • 两种异构体的口服清除率均被利福平同等增加约10倍。
  • 贝尼地平给药后心血管效应在对照组与利福平组之间无显著差异。

临床怎么用

  • 利福平可显著降低贝尼地平两对映体的血药浓度,临床合用时需关注贝尼地平疗效可能减弱。
  • 健康受试者中虽未见血压效应显著改变,但高血压患者合用时仍应监测血压控制情况。
  • 贝尼地平存在对映选择性处置,评估其暴露变化时应考虑异构体差异。
  • CYP3A活性(咪达唑仑清除率)不能替代贝尼地平口服清除率预测药物相互作用。

局限性

  • 研究仅在健康受试者中进行,结论不能直接外推至高血压患者。
  • 样本量未在摘要中报告。
  • 利福平对贝尼地平降压效应的影响仅在健康受试者中评估,患者中的治疗效应尚需研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In vitro study showed that benidipine is exclusively metabolized by cytochrome P450 (CYP) 3A. This study evaluated the effect of rifampin on the enantioselective disposition and anti-hypertensive effect of benidipine. METHODS: Benidipine (8 mg) was administered to healthy subjects with or without repeated rifampin dosing, in a crossover design. Plasma concentrations of (S)-(S)-(+)-α and (R)-(R)-(-)-α isomers of benidipine and blood pressure were measured for up to 24 h after dosing. In addition, CYP3A metabolic capacity was evaluated in each subject using oral clearance of midazolam. RESULTS: The exposure of (S)-(S)-(+)-α-benidipine was greater than that of (R)-(R)-(-)-α-benidipine by approximately three-fold following single dose of benidipine. Repeated doses of rifampin significantly decreased the exposure of both isomers. Geometric mean ratios (GMRs) (95% CI) of Cmax and AUC∞ for (S)-(S)-(+)-α-benidipine were 0.14 (0.10-0.18) and 0.12 (0.08-0.18), respectively. GMRs (95% CI) of Cmax and AUC∞ for (R)-(R)-(-)-α-benidipine were 0.10 (0.06-0.17) and 0.10 (0.06-0.17), respectively. Oral clearances of both isomers were increased equally by approximately 10-fold. There were no significant differences in cardiovascular effect following benidipine administration between control and rifampin treatment. CYP3A activity using midazolam did not appear to correlate with oral clearance of benidipine. CONCLUSIONS: After single administration of racemic benidipine, enantioselective disposition of (S)-(S)-(+)-α- and (R)-(R)-(-)-α-benidipine was observed. Treatments with rifampin significantly decreased the exposure of both isomers but appeared to marginally affect its blood pressure-lowering effect in healthy subjects. Impact of coadministration of rifampin on the treatment effects of benidipine should be assessed in hypertensive patients.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sunwoo YE, Nguyen PTT, Chien CM, et al. Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine. Br J Clin Pharmacol. 2019. PMID: 30589098. doi:10.1111/bcp.13848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。